Actively Recruiting
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
Led by University Health Network, Toronto · Updated on 2025-02-10
20
Participants Needed
1
Research Sites
342 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
CONDITIONS
Official Title
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who received previous radiotherapy to the prostate bed with or without pelvic nodal regions
- Prostate bed recurrence identified by biopsy, MRI, or PSMA PET scan
- At least two continuous PSA elevations after radiotherapy with PSA above 0.2 ng/dl
- PSA doubling time from nadir greater than 6 months, with or without androgen deprivation therapy
- ECOG performance status of 0 to 2
- Age greater than 18 years
You will not qualify if you...
- Evidence of distant metastases on PSMA PET, CT, MRI, or bone scan
- History of grade 3 or higher gastrointestinal or genitourinary toxicities after radiotherapy
- Any contraindications to MRI or brachytherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G1Z5
Actively Recruiting
Research Team
P
Peter Chung, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here